About
Liposomal Drugs for Cancer Treatment
Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposis sarcoma, and multiple myeloma. Co-founded by one of Doxils co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.
Identity
| Name | Ayana Pharma |
|---|---|
| Slug | ayana-pharma |
| Former names | DoxoCure |
| Type / kind | startup |
| Crunchbase ID | ayana-pharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgIvtgY4KDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Ein Kerem Street 95744, Jerusalem, Israel |
Web & social
| Website | https://www.ayanapharma.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersPatients
Business models
B2B
Tags
cancergeneric-drugsmedical-technologiesdrug-deliveryspace-techpharmaceuticalshospitals
Funding
| Total raised | — |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}